Antioxidant-dependent inhibition of diquat-induced toxicity in vivo.
The abilities of two experimental antioxidants (U-74006F and U-78517G), as well as the model antioxidant, diphenyl-p-phenylenediamine (DPPD), to protect against diquat-induced toxicity in male Fischer-344 rats were examined. Both experimental compounds afforded near complete protection against diquat-induced hepatotoxicity, as measured by clinical chemistry and histopathological indices. When observed, diquat-induced nephrotoxicity was also inhibited. Minimal protection was afforded by the model compound, DPPD. In follow-up studies with U-78517G, no effect on diquat-induced biliary excretion of oxidized glutathione was observed, suggesting that a shift in the thiol:disulfide ratio is not responsible for diquat-induced hepatotoxicity. These data are consistent with those from previous in vitro studies in our laboratory and are in agreement with studies by others which suggest that lipid peroxidation is an important event in diquat-induced hepatotoxicity in vivo. The antioxidant effects were largely route-independent as either oral pre-treatment alone (200 mg/kg, 24 h before diquat), intravenous pre-treatment alone (6 mg/kg, 5 min before diquat) or the combination of both treatments produced a similar degree of protection. While pre-treatment with antioxidants was quite effective, no significant U-78517G-dependent inhibition of toxicity was observed when administration was delayed by as little as 10 min post diquat. These latter data suggest that initiation of diquat-induced hepatotoxicity is rapid and that these compounds would therefore be unlikely to have clinical utility in the treatment of diquat intoxication.
Petry
T W
TW
Upjohn Laboratories, Upjohn Company, Kalamazoo, MI 49001.
Wolfgang
G H
GH
Jolly
R A
RA
Ochoa
R
R
Donarski
W J
WJ
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001806:Blood Urea Nitrogen; D056486:Chemical and Drug Induced Liver Injury; D002839:Chromans / Q000627:therapeutic use*; D004178:Diquat / Q000037:antagonists & inhibitors* / Q000633:toxicity; D007673:Kidney Cortex Necrosis / Q000139:chemically induced / Q000473:pathology; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control; D015227:Lipid Peroxidation / Q000187:drug effects; D008054:Lipid Peroxides / Q000037:antagonists & inhibitors; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008107:Liver Diseases / Q000201:enzymology / Q000517:prevention & control; D008297:Male; D009336:Necrosis; D010529:Peritoneal Cavity; D010655:Phenylenediamines / Q000493:pharmacokinetics / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use*; D011281:Pregnatrienes / Q000627:therapeutic use*; D051381:Rats; D011916:Rats, Inbred F344; D013997:Time Factors
D000975:Antioxidants; D002839:Chromans; D008054:Lipid Peroxides; D010655:Phenylenediamines; D010879:Piperazines; D011281:Pregnatrienes; C066382:U 78517F; D004178:Diquat; C004845:N,N'-diphenyl-4-phenylenediamine; D000410:Alanine Transaminase; C053355:tirilazad